Free Trial

Compass Therapeutics (CMPX) Competitors

Compass Therapeutics logo
$2.74 +0.01 (+0.18%)
As of 01:21 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CMPX vs. ETNB, ANIP, MESO, EWTX, JANX, TVTX, CVAC, CALT, GPCR, and AUPH

Should you be buying Compass Therapeutics stock or one of its competitors? The main competitors of Compass Therapeutics include 89BIO (ETNB), ANI Pharmaceuticals (ANIP), Mesoblast (MESO), Edgewise Therapeutics (EWTX), Janux Therapeutics (JANX), Travere Therapeutics (TVTX), CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), Structure Therapeutics (GPCR), and Aurinia Pharmaceuticals (AUPH). These companies are all part of the "pharmaceutical products" industry.

Compass Therapeutics vs. Its Competitors

89BIO (NASDAQ:ETNB) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

68.4% of Compass Therapeutics shares are held by institutional investors. 2.6% of 89BIO shares are held by insiders. Comparatively, 29.8% of Compass Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Compass Therapeutics has higher revenue and earnings than 89BIO. Compass Therapeutics is trading at a lower price-to-earnings ratio than 89BIO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
89BION/AN/A-$367.08M-$3.38-3.14
Compass Therapeutics$850K446.56-$49.38M-$0.41-6.70

In the previous week, 89BIO had 2 more articles in the media than Compass Therapeutics. MarketBeat recorded 2 mentions for 89BIO and 0 mentions for Compass Therapeutics. 89BIO's average media sentiment score of 0.00 equaled Compass Therapeutics'average media sentiment score.

Company Overall Sentiment
89BIO Neutral
Compass Therapeutics Neutral

Compass Therapeutics' return on equity of -42.47% beat 89BIO's return on equity.

Company Net Margins Return on Equity Return on Assets
89BION/A -81.44% -70.17%
Compass Therapeutics N/A -42.47%-38.31%

89BIO currently has a consensus price target of $26.43, suggesting a potential upside of 148.97%. Compass Therapeutics has a consensus price target of $12.67, suggesting a potential upside of 361.45%. Given Compass Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Compass Therapeutics is more favorable than 89BIO.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
89BIO
0 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
2 Strong Buy rating(s)
3.00
Compass Therapeutics
0 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
3.10

89BIO has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500.

Summary

Compass Therapeutics beats 89BIO on 11 of the 14 factors compared between the two stocks.

Get Compass Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CMPX vs. The Competition

MetricCompass TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$379.58M$2.96B$5.58B$9.01B
Dividend YieldN/A2.44%5.25%4.03%
P/E Ratio-6.7021.4727.5120.20
Price / Sales446.56259.84415.84172.51
Price / CashN/A41.8337.0657.97
Price / Book3.027.788.085.61
Net Income-$49.38M-$55.05M$3.17B$248.50M
7 Day Performance-1.08%5.38%3.57%4.92%
1 Month Performance9.36%3.87%3.74%7.42%
1 Year Performance188.31%5.72%33.78%21.48%

Compass Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CMPX
Compass Therapeutics
2.4686 of 5 stars
$2.75
+0.2%
$12.67
+361.4%
+216.4%$379.58M$850K-6.7020
ETNB
89BIO
1.554 of 5 stars
$9.82
-0.4%
$26.43
+169.1%
+31.2%$1.43BN/A-2.9140News Coverage
ANIP
ANI Pharmaceuticals
3.4293 of 5 stars
$65.25
-0.4%
$80.13
+22.8%
+6.5%$1.41B$614.38M-51.38600Analyst Forecast
MESO
Mesoblast
1.944 of 5 stars
$10.89
-0.3%
$18.00
+65.3%
+38.4%$1.39B$5.67M0.0080Positive News
EWTX
Edgewise Therapeutics
2.8239 of 5 stars
$13.11
-0.5%
$40.00
+205.1%
-38.3%$1.38BN/A-8.4660
JANX
Janux Therapeutics
1.4235 of 5 stars
$23.10
-0.2%
$95.25
+312.3%
-38.8%$1.37B$10.59M-16.9930
TVTX
Travere Therapeutics
3.1875 of 5 stars
$14.80
+0.2%
$32.14
+117.2%
+72.1%$1.31B$233.18M-5.27460
CVAC
CureVac
4.383 of 5 stars
$5.43
+0.9%
$6.83
+25.8%
+79.7%$1.22B$579.18M5.90880
CALT
Calliditas Therapeutics AB (publ)
N/A$40.00
flat
N/AN/A$1.19B$1.60B-21.62180
GPCR
Structure Therapeutics
2.6963 of 5 stars
$20.74
-1.6%
$76.17
+267.2%
-51.5%$1.19BN/A-23.84136
AUPH
Aurinia Pharmaceuticals
2.7487 of 5 stars
$8.47
-2.0%
$11.50
+35.8%
+52.0%$1.14B$235.13M30.25300

Related Companies and Tools


This page (NASDAQ:CMPX) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners